Brief: Compugen's Com701 Anti-Pvrig Induces Potent Immune Activation In Mss-Crc Patients
07/11/2022 13:36
Nov 7 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN'S COM701 (ANTI-PVRIG) INDUCES POTENT IMMUNE
ACTIVATION
IN MSS-CRC PATIENTS
Source text for Eikon: ID:nPnb81tnma
Further company coverage: CGEN.TA
((reuters.briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025